NEWTON, Mass.--(BUSINESS WIRE)--The senior management of Pro-Pharmaceuticals, Inc. (AMEX: PRW), has outlined strategic initiatives that will reallocate corporate resources in order to extend the Company’s cash runway and fund operations into December. The Company anticipates a 505 (b)(2) New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”) for DAVANAT® with 5-FU to treat advanced colorectal cancer with revenues to follow in 2009.
